Search
Stevenage, UK based TessellateBio recently signed a collaboration and licensing deal with Boehringer Ingelheim targeting tumors dependent on alternative lengthening of telomeres (ALT) for their growth
CEO Andree Blaukat describes TessellateBio's focus on synthetic lethality and the science behind this lead area they have partnered with...
7 hours ago
GENESIS Pharma is bringing global innovation closer to patients in Central and Eastern Europe
Already a partner for many of the world's top biopharma companies in this important region, see how GENESIS Pharma can help your company...
9 hours ago
BioVenture VoiCes Episode 19: Longwood Fund's Christoph Westphal
Dr. Westphal describes his upbringing and early career at McKinsey and Polaris, founding or co-founding companies like Momenta, Alnylam,...
1 day ago
Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs
CEO Arndt Schottelius describes the rationale behind the KnotBody platform and the company's future plans to develop them against things...
4 days ago
Meet NewBiologix, an innovative Swiss biotech company dedicated to revolutionizing the field of gene therapy
At #ASGCT2025, we met up with Founder and CEO Igor Fisch, who described the pillars that make NewBiologix a partner of choice in the rAAV...
4 days ago
ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk
CEO Alvin Luk and CTO TJ Cradick explain how the company's Cas12 and 13 programs are different than Cas9, and they discuss the DMD...
5 days ago
ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions
He talks about new capsids Dyno announced at this years' conference and the science behind getting them to specific places in the body....
5 days ago
ASGCT 2025: Physicians and scientists raced to make a bespoke gene editing therapy for an infant who urgently needed one in months - a first hand account, and what this means for drug development
As published in NEJM today , UPenn's Kiran Musunuru describes how the team used base editing in a matter of months to treat an infant...
5 days ago
ASGCT 2025: Coave Therapeutics presented a late breaker showing a positive profile for its cerebrospinal fluid administered ligand-engineered AAV2-based capsid
CEO Rodolphe Clerval walks us through Coave's "ALIGATER' ligand technology and describes the importance of the cerebrospinal administered...
5 days ago
Cambridge, UK based Alchemab Therapeutics last week signed a second collaboration with Eli Lilly worth up to $415M to license its IND ready program for ALS and other neurodegenerative diseases
CEO Jane Osbourn describes Alchemab's platform, which looks for people who are resilient to disease and then sequences them to understand...
5 days ago
ASGCT 2025: The Co-Founder of ProQR discusses the company's Axiomer RNA base editing technology - which will see a CTA filed this quarter and data by the end of the year
ProQR Co-Founder & CSO Gerard Platenburg describes the company's RNA editing platform and the journey he has seen this field go through...
5 days ago
ASGCT 2025: Capsida Biotherapeutics is using its expertise in capsid design to develop gene therapies that are tissue specific, and in the case of the CNS, can be delivered via IV and crosses the BBB
CEO Peter Anastasiou describes the importance of capsid design and how Caspida is developing its own gene therapies for CNS conditions. A...
6 days ago
ASGCT 2025: The co-founders of Circio describe the properties they believe make circular RNA a better, more durable medium for use in gene and cell therapies
CEO Erik Wiklund and CTO Thomas Hansen describe what circular RNA is, and explain their groundbreaking work where they discovered...
6 days ago
Gene therapies expert TJ Cradick previews what to watch for at the 2025 ASGCT Annual Meeting in New Orleans
He discusses the clinical programs, delivery vehicle advances, and safety improvements to watch for this year as the field of cell and...
7 days ago
Inductive Bio raised a $25M series A last week to continue its work utilizing AI to help drug developers in discovery understand a small molecule's ADMET properties before it is synthesized
Co-Founder & CEO Josh Haimson describes the pre-competitive data consortium that is harnessed by Inductive's Compass platform to do this...
May 13
NewLimit raised a $130M series B round last week to advance its work using epigenetic reprogramming to improve cell function and thus aim to extend longevity
Co-Founder & President Jacob Kimmel and Head of Operations Cathy O'Hare describe the scientific approach and how it benefits from the...
May 12
Biotech investor Christoph Broja of EQT Life Sciences discusses biotech in Europe and highlights portfolio companies Tubulis, Agomab Therapeutics, and PanTera
He describes the current environment for life sciences in Europe and how far it has come over the last ten years. Plus, his thoughts on...
May 9
With a phase 3 trial for its PRAME cell therapy underway and a data update coming up at ASCO, Immatics is pushing to be a leader in TCR based cell therapies and T-cell engagers
CEO Harpreet Singh joins us from the company's office in Munich, Germany, where he describes the founding of the company and previews...
May 9
Mosaic Therapeutics, which uses advanced computational methods and next-generation cancer models to design novel combination therapies, licensed an ERK1/2 and MDM2 inhibitor from Astex Pharmaceuticals
Interim CEO Magda Jonikas describes Mosaic's platform and the rationale behind these two targets the company has licensed in.
May 9
Cambridge, UK based Epitopia is helping Merck (MSD) discover tumor associated antigens from the non-coding regions of the genome using its CryptoMap platform
CEO Alan Rigby talks about the work Epitopia does finding "Crypotgen" antigens for its own off-the-shelf cancer vaccines, and discusses...
May 8
.png){kind=logo}
